A Provider Publication

#### **July 2021**

Focus on Behavioral Health

#### **Help Support Quality Care in Mental Health**

We encourage providers to talk with our members about their mental health, including signs of depression and anxiety in adults and children.

**Read More** 

#### Earn CME/CEU Credit at Free Webinar on Opioid Use

Join our board-certified psychiatrists and behavioral health medical directors on opioid use disorder on **Monday, Aug. 16, 2021**.

**Read More** 

# Pharmacy Program

#### Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2021 – Part 2

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions, revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) were made to the Blue Cross and Blue Shield of Illinois (BCBSIL) drug lists. Changes effective on or after **July 1, 2021**, are outlined <a href="here">here</a>.

#### Wellness and Member Education

#### In-home Test Kits for Colorectal Cancer Screening

BCBSIL is working with Home Access Health Corporation to provide in-home test kits for certain

members who need a colorectal cancer screening.

**Read More** 

### Blue Door Neighborhood Center<sup>SM</sup> Celebrates Physical Opening of Locations

Join us for an outdoor event to celebrate the physical opening of the Blue Door Neighborhood Center (BDNC<sup>SM</sup>) in South Lawndale on July 12, 2021, from noon to 2 p.m.

**Read More** 

## Network Innovation/Product Updates

#### Closing Gaps in Care for Group Medicare Advantage (MA) Members

The Blue Cross and Blue Shield (BCBS) National Coordination of Care program is again serving **Blue Cross Group Medicare Advantage (PPO)**<sup>SM</sup> (Group MA PPO) members.

**Read More** 

### **Blue Choice Opt PPO<sup>SM</sup> Network Expanding to All Illinois Counties**

Effective **July 1, 2021**, BCBSIL expanded our Blue Choice Opt PPO network (BCO) to cover all Illinois counties.

**Read More** 

# Electronic Options

#### Check Eligibility and Benefits: Don't skip this important first step!

Is your patient's membership with BCBSIL still active? Are you or your practice/medical group in- or out-of-network for a specific patient? Is prior authorization required for a particular member/service?

**Read More** 

# Clinical Updates, Reminders and Resources

# New Video Features Medical Director Insights on Prior Authorization and Related Processes

We're continuing to refine the Utilization Management section on our Provider website. Recently, we added a new <u>Utilization Management: Medical Director Video</u>. It includes four short videos from members on our Medical Director team. Choose from a menu of four topics: Terminology Overview, Intake Process, Peer-to-Peer Process, or Appeals. View one or all of the videos, in any order. If you have questions or feedback, there's a link to a survey. We value your input!

# Claims and Coding

#### BlueCard® Program Reminder Checklist

The BlueCard program is designed to help our members take their coverage with them when they travel. It also offers providers access to an electronic network for claim submission and reimbursement.

**Read More** 

#### Provider Education

#### **Provider Learning Opportunities**

BCBSIL offers free webinars and workshops for the independently contracted providers who work with us. A preview of upcoming training sessions is included in this month's issue.

**Read More** 

#### Notification and Disclosure

#### **Important Dates and Reminders**

<u>Check here</u> each month for a quick snapshot of recent implementations, upcoming changes, special events, important deadlines and other reminders.

#### **Reminder: CPT Codes May Change**

As a reminder, CPT codes may change throughout the year due to changes (new, replaced or removed codes) implemented by the American Medical Association (AMA).

**Read More** 



#### Stay informed!

Watch the News and Updates on our Provider website for important announcements.

#### **Update Your Information**

Do you need to update your location, phone number, email or other important details on file with BCBSIL? Use our online forms to <u>request an information change</u>.

#### **Provider Training**

For dates, times and online registration, visit the Webinars and Workshops page.



# bcbsil.com

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

300 E. Randolph Street, Chicago, IL 60601

© Copyright 2021. Health Care Service Corporation. All Rights Reserved.

Legal and Privacy | Unsubscribe

A newsletter for contracting institutional and professional providers

July 2021

#### **Help Support Quality Care in Mental Health**

Mental health conditions are common, affecting people of all ages. The <u>Centers for Disease Control and Prevention</u> (CDC) estimates that half of Americans will be diagnosed with a mental illness or disorder at some point in their lives. The number of Americans seeking help for mental health has increased <u>during the pandemic</u>. We encourage providers to talk with our members about mental health awareness, including signs of depression and anxiety in <u>adults</u> and <u>children</u>. Consider using a depression screener in your office, such as the <u>nine-question patient health questionnaire (PHQ-9)</u>, and encourage members to get help if needed.

#### **Closing Care Gaps**

As part of monitoring and helping improve quality of care, we track two measures related to mental health:

- Follow-up after Hospitalization for Mental Illness (FUH)<sup>2</sup>
- Follow-up after Emergency Department (ED) Visit for Mental Illness (FUM)<sup>3</sup>

Both are Healthcare Effectiveness Data and Information Set (HEDIS®) measures from the National Committee for Quality Assurance (NCQA). Follow-up care for people with mental illness is linked to fewer repeat emergency department (ED) visits and improved physical and mental function, according to NCQA.

#### **About FUH**

As defined by NCQA, FUH applies to members ages 6 and older who had a follow-up visit with a mental health provider after they were hospitalized for the "treatment of selected mental illness or intentional self-harm." FUH captures the percentage of discharges for which members had a follow-up visit:

- Within 30 days of discharge (31 total days)
- Within seven days of discharge (8 total days)

#### **About FUM**

FUM focuses on behavioral health follow-up visits after an ED visit for members ages 6 and older with a diagnosis of mental illness, according to NCQA. FUM captures the percentage of ED visits for which members had a follow-up visit:

- Within 30 days of discharge (31 total days)
- Within seven days of discharge (8 total days)

For more information about the FUH and FUM quality measure, see our <u>HEDIS tip sheets</u>.

#### **Tips to Consider**

#### For EDs and hospitals:

- Help our members schedule an in-person or telehealth follow-up visit with a behavioral health provider within seven days of discharge. The follow-up visit must be on a different date than the discharge date.
- Educate members about the importance of following up with treatment.
- Focus on member preference for treatment, allowing members to take ownership of the treatment process.

#### For providers:

- Encourage members to bring their discharge paperwork to their first appointment.
- Educate members about the importance of following up and adhering to treatment recommendations.
- Use the same diagnosis for mental illness at each follow-up visit. A non-mental illness diagnosis code will not fulfill this
  measure.
- Coordinate care between behavioral health and primary care providers.
  - Share progress notes and updates.
  - · Include the diagnosis for mental illness
  - Reach out to members who cancel appointments and help them reschedule as soon as possible.

The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider. HEDIS is a registered trademark of the NCQA.

#### bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

<sup>&</sup>lt;sup>1</sup> CDC, Learn About Mental Health, Jan. 26, 2018. <a href="https://www.cdc.gov/mentalhealth/learn/index.html">https://www.cdc.gov/mentalhealth/learn/index.html</a>

<sup>&</sup>lt;sup>2</sup> NCQA, Follow-Up After Hospitalization for Mental Illness (FUH), <a href="https://www.ncqa.org/hedis/measures/follow-up-after-hospitalization-for-mental-illness/">https://www.ncqa.org/hedis/measures/follow-up-after-hospitalization-for-mental-illness/</a>

<sup>3</sup> NCQA, Follow-Up After Emergency Department Visit for Mental Illness (FUM), https://www.ncqa.org/hedis/measures/follow-up-after-emergency-department-visit-for-mental-illness/

A newsletter for contracting institutional and professional providers

July 2021

### Earn CME/CEU Credit at Free Webinar on Opioid Use

Join our board-certified psychiatrists and behavioral health medical directors for a one-hour webinar on opioid use disorder. The webinar is on **Monday**, **Aug. 16**, **2021**, **at 8 a.m.**, **CT**. It's free to providers. Those who attend will earn one continuing medical education credit (CME) or continuing education unit (CEU).

The webinar will provide a high-level overview of the assessment and treatment of opioid use disorder in a primary care setting. This introductory training focuses on substance abuse in the primary care setting, with treatment options across settings.

#### How do I attend?

Registration is required. Visit our Webinars and Workshops page for more information and online registration. Or, <u>register</u> now.

#### **Future CME/CEU Offering**

We will offer a free webinar on comorbid behavioral health and physical health conditions on Oct. 25, 2021.

Watch the News and Updates and our Webinars and Workshops page for details on these trainings.

The New Mexico Osteopathic Medical Association (NMOMA) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. NMOMA designates this program for a maximum of 1 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation.

Social Work CEUs Approved by NASW-NM. The Licensee must maintain proof of continuing education courses taken for the past four (4) years. The New Mexico Regulations and Licensing Department, Boards and Commissions, Social Work Licensing Board reserves the right to audit a licensee's continuing education records as it deems necessary. This event has been approved for a total of 1 CEU.

Physicians (MDs and DOs), nurses, physician assistants and nurse practitioners can use AOA Cat 1-4 credit toward licensure. Psychologists, social workers and mental health counselors (LPC, LCPC, LCPC) can use the Social Work CEU credit toward licensure.

Material presented is for informational purposes only and is not intended to be a substitute for the independent medical judgment of a physician. Physicians and other health care providers are encouraged to use their own best medical judgment based upon all available information and the condition of the patient in determining the best course of treatment. The fact that a service or treatment is described is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

#### bcbsil.com/provider

#### Association



# Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2021 – Part 2

Posted June 9, 2021

This article is a continuation of the previously published *Quarterly Pharmacy Changes Part 1* article. While that Part 1 article included the drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates, this Part 2 version contains the more recent coverage additions, utilization management updates and any other updates to the pharmacy program.

#### **DRUG LIST CHANGES**

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of Illinois (BCBSIL) drug lists.

Please note: Revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) were included in the *Quarterly Pharmacy Changes Part 1* article. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes.

#### Changes effective July 1, 2021 are outlined below.

Drug List Coverage Additions - As of July 1, 2021

| Drug List Coverage Additions – As of July 1, 2021  |  |  |
|--|--|--|
| Drug <sup>1</sup>  | Drug Class/Condition Used For                |  |
| Basic, Basic Annual, Multi-Tier Basic, Multi-Tier Basic Annual, Enhanced, Enhanced Annual, |  |  |
| Multi-Tier Enhanced and Multi-Tier Enhanced Annual Drug Lists                              |  |  |
| CARBAGLU (carglumic acid tab 200 mg)   | Hyperammonemia                               |  |
| KESIMPTA (ofatumumab soln auto-injector 20 mg/0.4  | Relapsing Multiple Sclerosis                 |  |
| ml)  |  |  |
| LATUDA (lurasidone hcl tab 20 mg, 40 mg, 60 mg, 80   | Schizophrenia, Bipolar Depression            |  |
| mg, 120 mg)  |  |  |
| MAYZENT STARTER PACK (siponimod fumarate tab   | Relapsing Multiple Sclerosis                 |  |
| 0.25 mg (12) starter pack)   |  |  |
| NYVEPRIA (pegfilgrastim-apgf soln prefilled syringe 6                                      | Neutropenia                                  |  |
| mg/0.6 ml)   |  |  |
| OZEMPIC (semaglutide soln pen-inj 1 mg/dose (4 mg/3  | Diabetes                                     |  |
| ml))   |  |  |
| PLEGRIDY (peginterferon beta-1a im soln prefilled syr                                      | Relapsing Multiple Sclerosis                 |  |
| 125 mcg/0.5 ml)  |  |  |
| REDITREX (methotrexate soln prefilled syringe 7.5  | Rheumatoid Arthritis, Polyarticular Juvenile |  |
| mg/0.3 ml, 10 mg/0.4 ml, 12.5 mg/0.5 ml, 15 mg/0.6 ml,                                     | Idiopathic Arthritis, Psoriasis              |  |
| 17.5 mg/0.7 ml, 20 mg/0.8 ml, 22.5 mg/0.9 ml, 25 mg/ml)                                    |  |  |
| VIMPAT (lacosamide oral solution 10 mg/ml)   | Seizures                                     |  |
| VIMPAT (lacosamide tab 50 mg, 100 mg, 150 mg, 200  | Seizures                                     |  |
| mg)  |  |  |
| XELJANZ (tofacitinib citrate oral soln 1 mg/ml (base                                       | Rheumatoid Arthritis, Polyarticular Juvenile |  |
| equivalent))   | Idiopathic Arthritis, Psoriatic Arthritis,   |  |
|  | Ulcerative Colitis                           |  |
| XTANDI (enzalutamide tab 40 mg, 80 mg)   | Prostate Cancer                              |  |
| ZOKINVY (lonafarnib cap 50 mg, 75 mg)  | Progeria                                     |  |

| Enhanced Enhanced Annual Multi Tier Enhanced on                  | d Multi Tier Enhanced Annual Drug Liete  |
|--|--|
| Enhanced, Enhanced Annual, Multi-Tier Enhanced an                |  |
| AFINITOR (everolimus tab 10 mg)                                  | Cancer   |
| ARANESP ALBUMIN FREE (darbepoetin alfa soln inj 25               | Anemia   |
| mcg/ml, 40 mcg/ml, 60 mcg/ml, 100 mcg/ml, 200 mcg/ml,            |  |
| 300 mcg/ml)  |  |
| ARANESP ALBUMIN FREE (darbepoetin alfa soln                      | Anemia   |
| prefilled syringe 10 mcg/0.4 ml, 150 mcg/0.3 ml, 500             |  |
| mcg/ml)  |  |
| AZITHROMYCIN (azithromycin powd pack for susp 1                  | Infections   |
| gm)  |  |
| COMBIVENT RESPIMAT (ipratropium-albuterol inhal                  | Chronic Obstructive Pulmonary Disease  |
| aerosol soln 20-100 mcg/act)                                     | (COPD)   |
| COTELLIC (cobimetinib fumarate tab 20 mg (base                   | Cancer   |
| equivalent))   |  |
| CRINONE (progesterone vaginal gel 4%, 8%)                        | Infertility  |
| DILANTIN (phenytoin sodium extended cap 30 mg)                   | Seizures   |
| EMCYT (estramustine phosphate sodium cap 140 mg)                 | Cancer   |
| LOTEMAX (loteprednol etabonate ophth oint 0.5%)                  | Ophthalmic Inflammatory Conditions   |
| LOTEMAX SM (loteprednol etabonate ophth gel 0.38%)               | Ophthalmic Inflammatory Conditions   |
| LUMIGAN (bimatoprost ophth soln 0.01%)                           | Ocular Hypertension, Glaucoma  |
| MESNEX (mesna tab 400 mg)  | Hemorrhagic Cystitis   |
| MULTAQ (dronedarone hcl tab 400 mg (base                         | Atrial Fibrillation  |
| equivalent))   | 7 11.13.1 7 13.1113.113.11   |
| NEULASTA (pegfilgrastim soln prefilled syringe 6 mg/0.6          | Neutropenia  |
| ml)  | Trout oportion   |
| NEULASTA ONPRO KIT (pegfilgrastim soln prefilled                 | Neutropenia  |
| syringe kit 6 mg/0.6 ml)   | Trout oportion   |
| NEXIUM (esomeprazole magnesium for delayed release               | Gastroesophageal Reflux Disease (GERD)   |
| susp pack 2.5 mg, 5 mg)  | Caotroscophagoar Ronax Bloodoo (CERE)  |
| PREDNISOLONE SODIUM PHOSPHATE (prednisolone                      | Ophthalmic Inflammatory Conditions   |
| sodium phosphate ophth soln 1%)                                  | Ophiliannio innaminatory Conditions  |
| PREDNISONE (prednisone oral soln 5 mg/5 ml)                      | Inflammatory Conditions  |
| PRENATAL 19 (prenatal vit w/ dss-fe fumarate-fa tab 29-          | Prenatal Vitamin   |
| 1 mg)  |  |
| PRENATAL 19 (prenatal vit w/ fe fumarate-fa chew tab             | Prenatal Vitamin   |
| 29-1 mg)   |  |
| PROPRANOLOL HCL (propranolol hcl oral soln 20 mg/5               | Hypertension   |
| ml, 40 mg/5 ml)  | Trypertension  |
| PURIXAN (mercaptopurine susp 2000 mg/100ml (20                   | Concor   |
| ` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '                          | Cancer   |
| mg/ml)) SE-NATAL 19 (prenatal vit w/ dss-fe fumarate-fa tab 29-1 | Dranatal Vitamin   |
| "  | Prenatal Vitamin   |
| mg)  | December 1976 and a  |
| SE-NATAL 19 (prenatal vit w/ fe fumarate-fa chew tab             | Prenatal Vitamin   |
| 29-1 mg)   | On leading of the control of the con |
| SIMBRINZA (brinzolamide-brimonidine tartrate ophth               | Ocular Hypertension, Glaucoma  |
| susp 1-0.2%)   | Dishetes   |
| SYNJARDY (empagliflozin-metformin hcl tab 5-500 mg,              | Diabetes   |
| 5-1000 mg, 12.5-500 mg, 12.5-1000 mg)                            |  |
| SYNJARDY XR (empagliflozin-metformin hcl tab er 24hr             | Diabetes   |
| 5-1000 mg, 10-1000 mg, 12.5-1000 mg, 25-1000 mg)                 |  |
| TABLOID (thioguanine tab 40 mg)                                  | Cancer   |
| VELPHORO (sucroferric oxyhydroxide chew tab 500 mg)              | Chronic Kidney Disease   |

| VYVANSE (lisdexamfetamine dimesylate cap 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg)  | Attention Deficit Hyperactivity Disorder (ADHD)  |  |
|--|--|--|
| VYVANSE (lisdexamfetamine dimesylate chew tab 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg)  | Attention Deficit Hyperactivity Disorder (ADHD)  |  |
| ZYLET (loteprednol etabonate-tobramycin ophth susp 0.5-0.3%)   | Ophthalmic Inflammatory Conditions   |  |
| 0.0 0.070)   |  |  |
| Balanced, Performance, Performance Annual a  | and Performance Select Drug Lists  |  |
| abiraterone acetate tab 500 mg (generic for ZYTIGA)  | Cancer   |  |
| emtricitabine-tenofovir disoproxil fumarate tab 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg   | HIV/HIV Prophylaxis  |  |
| ERYTHROMYCIN ETHYLSUCCINATE (erythromycin ethylsuccinate tab 400 mg)   | Infections   |  |
| glucagon (rdna) for inj kit 1 mg (generic for GLUCAGON EMERGENCY KIT)  | Hypoglycemia   |  |
| HUMIRA PEN (adalimumab pen-injector kit 80 mg/0.8 ml)  | Rheumatoid Arthritis, Psoriatic Arthritis,<br>Ankylosing Spondylitis, Crohn's Disease,<br>Ulcerative Colitis, Plaque Psoriasis         |  |
| HUMIRA PEN-PEDIATRIC UC STARTER PACK (adalimumab pen-injector kit 80 mg/0.8 ml)  | Rheumatoid Arthritis, Psoriatic Arthritis,<br>Ankylosing Spondylitis, Crohn's Disease,<br>Ulcerative Colitis, Plaque Psoriasis         |  |
| ICLUSIG (ponatinib hcl tab 10 mg, 30 mg (base equivalent))   | Leukemia   |  |
| IMCIVREE (setmelanotide acetate subcutaneous soln 10 mg/ml)  | Obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency |  |
| JANSSEN COVID-19 VACCINE (covid-19 (sars-cov-2) ad26 vector vaccine-janssen im 0.5 ml)   | COVID-19 Vaccine   |  |
| KESIMPTA (ofatumumab soln auto-injector 20 mg/0.4 ml)  | Relapsing Multiple Sclerosis   |  |
| loteprednol etabonate ophth gel 0.5% (generic for LOTEMAX GEL)   | o (generic for Ophthalmic Conditions   |  |
| MAYZENT STARTER PACK (siponimod fumarate tab 0.25 mg (12) starter pack)  | Relapsing Multiple Sclerosis   |  |
| MODERNA COVID-19 VACCINE (covid-19 (sars-cov-2) mrna vacc-moderna im susp 100 mcg/0.5 ml)  | COVID-19 Vaccine   |  |
| NYVEPRIA (pegfilgrastim-apgf soln prefilled syringe 6 mg/0.6ml)  | Chemotherapy-Induced Neutropenia   |  |
| ORGOVYX (relugolix tab 120 mg)   | Prostate Cancer  |  |
| OZEMPIC (semaglutide soln pen-inj 1 mg/dose (4 mg/3 ml))   | Diabetes   |  |
| PLEGRIDY (peginterferon beta-1a im soln prefilled syr 125 mcg/0.5 ml)  | Relapsing Multiple Sclerosis   |  |
| REDITREX (methotrexate soln prefilled syringe 7.5 mg/0.3 ml, 10 mg/0.4 ml, 12.5 mg/0.5 ml, 15 mg/0.6 ml, 17.5 mg/0.7 ml, 20 mg/0.8 ml, 22.5 mg/0.9 ml, 25 mg/ml) | Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis  |  |
| THYQUIDITY (levothyroxine sodium oral solution 100 mcg/5 ml)   | Hypothyroidism   |  |
| VAXELIS (diph-tet tox-ac pert ad-polio ipv-hib-hep b rec susp pre syr)   | Vaccine  |  |
| VAXELIS (diph-tet tox-ac pert ad-polio ipv-hib-hepatitis b recmb susp)   | Vaccine  |  |
| XELJANZ (tofacitinib citrate oral soln 1 mg/ml (base equivalent))  | Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis  |  |

| XTANDI (enzalutamide tab 40 mg, 80 mg)  | Prostate Cancer                          |  |
|---|--|--|
| ZOKINVY (lonafarnib cap 50 mg, 75 mg)   | Progeria                                 |  |
| XHANCE (fluticasone propionate nasal exhaler susp 93  | Nasal Polyps                             |  |
| mcg/act)  | Tracai i ciype                           |  |
| - magraciy  |  |  |
| Balanced and Performance S  | Select Drug Lists                        |  |
| brinzolamide ophth susp 1%  | Glaucoma, Ocular Hypertension            |  |
| imiquimod cream 3.75% (generic for ZYCLARA)   | Actinic Keratosis                        |  |
| JORNAY PM (methylphenidate hcl cap delayed er 24hr  | Attention-Deficit Hyperactivity Disorder |  |
| 20 mg, 40 mg, 60 mg, 80 mg, 100 mg (pm))  | (ADHD)                                   |  |
| WINLEVI (clascoterone cream 1%)   | Acne                                     |  |
|   |  |  |
| Balanced Drug List  |  |  |
| azelastine hcl-fluticasone prop nasal spray 137-50  | Allergic Rhinitis                        |  |
| mcg/act (generic for DYMISTA)   |  |  |
| droxidopa cap 100 mg, 200 mg, 300 mg (generic for   | Neurogenic Orthostatic Hypotension       |  |
| NORTHERA)   |  |  |
| hydrocodone bitartrate tab er 24hr deter 20 mg, 30 mg,  | Pain                                     |  |
| 40 mg, 60 mg, 80 mg, 100 mg, 120 mg (generic for  |  |  |
| HYSINGLA ER)  |  |  |
| IMPEKLO (clobetasol propionate lotion 0.15 mg/act   | Topical Inflammation/Itching             |  |
| (0.05%))  |  |  |
| NAPROXEN SODIUM (naproxen sodium tab er 24hr 750  | Pain, Inflammation                       |  |
| mg (base equivalent)) (authorized generic for   |  |  |
| NAPRELAN)   | Daykinson's Disease                      |  |
| ONGENTYS (opicapone cap 25 mg) OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN                                | Parkinson's Disease                      |  |
|   | Pain                                     |  |
| (oxycodone w/ acetaminophen soln 10-300 mg/5 ml) PREGEN DHA (prenatal mv & min w/fe carbonyl-fa-dha | Propostal Vitamin                        |  |
| cap 28-1-35 mg)   | Prenatal Vitamin                         |  |
| PROLATE (oxycodone w/ acetaminophen soln 10-300   | Dain                                     |  |
| mg/5 ml)  | Pain                                     |  |
| QDOLO (tramadol hcl oral soln 5 mg/ml)  | Pain                                     |  |
| RELTONE (ursodiol cap 200 mg, 400 mg)   | Gallstones                               |  |
| SULCONAZOLE NITRATE (sulconazole nitrate solution   | Fungal Infections                        |  |
| 1%) (authorized generic for EXELDERM SOLN)  |  |  |
| TRISTART FREE (prenat w/o a w/dha & fecbn-methylf-fa  | Prenatal Vitamin                         |  |
| cap 33-1 mg)  |  |  |

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

Drug List Updates (Coverage Tier Changes) – As of July 1, 2021

| Drug <sup>1</sup>   | New Lower Tier        | Drug Class/Condition Used For   |  |
|---|-----------------------|---------------------------------|--|
| Balanced, Performance, Performance Annual and Performance Select Drug Lists |                       |                                 |  |
| CARBAGLU (carglumic acid tab 200 mg)  | Preferred Brand       | Hyperammonemia                  |  |
| ESTRING (estradiol vaginal ring 2 mg  | Preferred Brand       | Menopause Symptoms              |  |
| (7.5 mcg/24hrs))  |                       |                                 |  |
| LATUDA (lurasidone hcl tab 20 mg, 40  | Preferred Brand       | Bipolar Disorder, Schizophrenia |  |
| mg, 60 mg, 80 mg, 120 mg)   |                       |                                 |  |
| norelgestromin-ethinyl estradiol td ptwk                                    | Non-Preferred Generic | Contraceptive                   |  |
| 150-35 mcg/24hr (XULANE)  |                       |                                 |  |
| promethazine & phenylephrine syrup  | Non-Preferred Generic | Cold & Allergies                |  |
| 6.25-5 mg/5 ml  |                       |                                 |  |

| promethazine-phenylephrine-codeine<br>syrup 6.25-5-10 mg/5 ml | Non-Preferred Generic  | Cough/Cold                      |
|---|------------------------|---------------------------------|
| terconazole vaginal cream 0.8%                                | Non-Preferred Generic  | Yeast Infections                |
| topiramate cap er 24hr sprinkle 25 mg,                        | Non-Preferred Generic  | Seizures                        |
| 50 mg, 100 mg, 150 mg, 200 mg                                 |                        |                                 |
| (generic for QUDEXY XR)                                       |                        |                                 |
| VIMPAT (lacosamide oral solution 10                           | Preferred Brand        | Seizures                        |
| mg/ml)  |                        |                                 |
| VIMPAT (lacosamide tab 50 mg, 100                             | Preferred Brand        | Seizures                        |
| mg, 150 mg, 200 mg)   |                        |                                 |
|   |                        |                                 |
| Balanced and  | Performance Select Dru | ıg Lists                        |
| imiquimod cream 3.75%   | Non-Preferred Generic  | Actinic Keratosis               |
| QUILLICHEW ER (methylphenidate hcl                            | Preferred Brand        | Attention-Deficit Hyperactivity |
| chew tab extended release 20 mg, 30                           |                        | Disorder (ADHD)                 |
| mg, 40 mg)  |                        |                                 |
| QUILLIVANT XR (methylphenidate hcl                            | Preferred Brand        | Attention-Deficit Hyperactivity |
| for er susp 25 mg/5 ml (5 mg/ml))                             |                        | Disorder (ADHD)                 |
|   |                        |                                 |
| Balanced Drug List  |                        |                                 |
| levorphanol tartrate tab 3 mg                                 | Non-Preferred Generic  | Pain                            |

<sup>&</sup>lt;sup>1</sup>Third-party brand names are the property of their respective owner.

#### **UTILIZATION MANAGEMENT PROGRAM CHANGES**

- Effective **June 1, 2021**, the Imcivree Specialty Prior Authorization (PA) program and target drug Imcivree will be added to the Basic, Basic Annual, Enhanced, Enhanced Annual, Balanced, Performance, Performance Annual and Performance Select Drug Lists.
- Effective **July 1, 2021**, the following changes will be applied:
  - The Benlysta Specialty PA program will change its name to Lupus. The program includes the same targeted medication and a new one, Lupkynis, which applies to the Balanced, Performance, Performance Annual and Performance Select Drug Lists. The program criteria will also be updated as needed.
  - The Circadian Rhythm Disorders PA program will change its name to Hetlioz. The
    program includes the same targeted medication and a new one, Hetlioz LQ. The program
    criteria will also be updated as needed.
  - The Coagulation Factor VIIa Specialty PA program and target drugs NovoSeven RT and Sevenfact will be added to the Basic, Basic Annual, Enhanced, Enhanced Annual, Balanced, Performance, Performance Annual and Performance Select Drug Lists.
  - The Zokinvy PA program and target drug Zokinvy will be added to the Balanced, Performance, Performance Annual and Performance Select Drug Lists.

For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit *bcbsil.com* and log in to Blue Access for Members<sup>SM</sup> (BAM<sup>SM</sup>) or MyPrime.com for a variety of online resources.

#### Reminder: Split Fill Program Available to Select Members

BCBSIL offers its members and groups a Split Fill program to reduce waste and help avoid costs of select specialty medications that may go unused. Members new to therapy (or have not had claims history within the past 120 days for the drug) are provided partial, or "split," prescription fills for up to three months.

The Split Fill Program applies to a specific list of drugs known to have early discontinuation or dose modification. You can view the current list of drugs and find more information on the *Split Fill Program* on our Provider website.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

#### **HDHP-HSA Preventive Drug Program Reminder**

Select BCBSIL members' High Deductible Health Plan (with a Health Savings Account) may include a preventive drug program, which offers a reduced cost share for members using certain medications for preventive purposes. *Please note:* If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under their preventive drug benefit may also change.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

#### **HIV Pre-Exposure Prophylaxis (PrEP) Coverage Updates**

As a reminder, the brand Truvada 200-300 mg will be removed from coverage under the HIV Pre-exposure Prophylaxis (PrEP) ACA category effective July 1, 2021 and may not be covered on the member's drug list. This change applies to members with an ACA-compliant plan and on one of the following drug lists: Basic, Enhanced, Balanced, Performance, Performance Select and IL Non-HMO Health Insurance Marketplace. Members who are affected by this change were notified prior to the effective date. If you have patients with an HMO Illinois® or Blue Advantage HMO<sup>SM</sup> plan, this change may not apply to their pharmacy benefits, administered through Prime Therapeutics, until on or after Jan. 1, 2022.

Emtricitabine-tenofovir disoproxil fumarate tab 200-300 mg (generic for Truvada 200-300 mg) is available at \$0 if members meet the conditions set under ACA.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSIL contracts with Prime to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.

A newsletter for contracting institutional and professional providers

July 2021

### In-home Test Kits for Colorectal Cancer Screening

Blue Cross and Blue Shield of Illinois (BCBSIL) is working with Home Access Health Corporation to provide in-home test kits for certain members who need a colorectal cancer screening. Because of the COVID-19 pandemic, many may have delayed getting appropriate care. Home Access Health is sending Fecal Immunochemical Test (FIT) kits to certain Blue Choice Preferred PPO<sup>SM</sup> members at no additional charge.

#### **How It Works**

The process is quick and easy for members to follow:

- Home Access Health sends the kits to a sample of eligible members who've been identified with a gap in care for colorectal cancer screening. Completing the kit is voluntary.
- The kits don't require fasting, dietary restrictions or preparation. Medications are taken according to members' normal schedule.
- Members complete the test kit at home, provide the name of their primary care physician (PCP) and mail the test for processing to Home Access Health by Dec. 31, 2021. An addressed, postage-paid envelope is included.
- Home Access Health sends results to the member and their PCP in three to four weeks.

#### **How You Can Help**

As a trusted provider, you may want to encourage our members to take advantage of this opportunity to learn more about their health.

- Discuss the importance of colorectal cancer screening and healthy lifestyle choices with our members.
- If our member receives a kit and calls your office with questions, discuss their screening options.
- Document any test results in the member's medical record and discuss the results with our member.

#### **FIT Testing**

- The <u>U.S. Multi-Society Task Force on Colorectal Cancer</u> recognizes annual FIT testing and colonoscopy as the two
  cornerstones of screening every 10 years.
- FIT testing is appropriate screening for individuals with an average risk for colorectal cancer. Average risk means no
  family history of colorectal cancer, no personal history of inflammatory bowel disease, no previous polyps and no
  previous colorectal cancer.

Home Access Health Corporation is an independent company that provides health screenings for BCBSIL. Home Access Health Corporation is solely responsible for the products and services it provides

Material presented is for informational purposes only and is not intended to be a substitute for the independent medical judgment of a physician. Physicians and other health care providers are encouraged to use their own best medical judgment based upon all available information and the condition of the patient in determining the best course of treatment.

# bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

A newsletter for contracting institutional and professional providers

July 2021

## Blue Door Neighborhood Center<sup>SM</sup> Celebrates Physical Opening of Locations

Join us for an outdoor event to **celebrate the physical opening of the Blue Door Neighborhood Center** (BDNC<sup>SM</sup>) in South Lawndale on **Monday**, **July 12**, **2021**, **from noon to 2 p.m.** Meet our staff, tour the center and pick up some produce at our farmers market. Invite your patients and staff, and bring your family for entertainment and music.

Come one, come all to the **block party at the BDNC in Pullman** on **Saturday, July 17, from 11 a.m. to 3 p.m.** The family-centered block party will feature:

- · Music and food
- 40+ double-dutch and South Shore drill teams
- Balloon artist
- Care Van<sup>®</sup>
- Health information
- · Low-impact fitness demos

In July, we're also hosting **Minority Mental Health Month** events such as:

- Mental Health Disparities in the Latino and Black Populations
- Coping with Stress
- Fall Prevention for Seniors
- Bingocize® Bingo with fall prevention exercises
- Zumba<sup>®</sup> for seniors

As with all programming at BDNC, events and classes are free and open to BCBSIL members and non-members.

These are just a few of the programs we'll offer at our BDNC sites on multiple dates and times in July. Encourage your patients to check the online calendars at <u>BDNC at Morgan Park</u>, <u>BDNC at Pullman</u> and <u>BDNC at South Lawndale</u> for details and to register. They can also visit the <u>BDNC Facebook page</u> for other events and happenings at all three locations. If you or your patients have questions, <u>email the BDNC</u> or call 773-253-0900.

care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. References to third party sources or organizations are not a representation, warranty or endorsement of such organizations. Any questions regarding those organizations should be addressed to them directly. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

# bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

A newsletter for contracting institutional and professional providers

July 2021

### **Closing Gaps in Care for Group Medicare Advantage (MA) Members**

The Blue Cross and Blue Shield (BCBS) **National Coordination of Care** program is again serving **Blue Cross Group Medicare Advantage (PPO)**<sup>SM</sup> (Group MA PPO) members. The program paused during the global pandemic. As we told you in <u>January 2020</u>, the program supports continuity of care for all BCBS Group MA PPO members.

#### What This Means for Medicare Providers

Blue Cross and Blue Shield of Illinois (BCBSIL) will work with you to help close gaps in care for BCBSIL and other BCBS Group MA PPO members. If we need medical records, you won't receive requests from multiple BCBS plans or their vendors. You will receive requests only from BCBSIL or our vendor, Change Healthcare. We may request medical records for:

- Risk adjustment gaps related to claims submitted to BCBSIL
- Healthcare Effectiveness Data and Information Set (HEDIS®) measures
- Centers for Medicare & Medicaid Services (CMS) Star Ratings

#### **Important Reminders**

- Respond quickly to requests related to risk adjustment, HEDIS and other government-required activities as your contract requires.
- You don't need patient-authorized information releases to fulfill medical records requests and risk adjustment gaps through this program.
- Use the <u>Availity® Provider Portal</u> or your preferred vendor to verify BCBSIL and other BCBS members' eligibility and benefits before every appointment. Eligibility and benefit quotes include:
  - Membership verification
  - Coverage status
  - Prior authorization requirements
  - Provider's network status for the patient's policy
  - Applicable copayment, coinsurance and deductible amounts
- Ask to see the member's ID card and a photo ID to help guard against medical identity theft.
- Notify members that they may be billed directly when services may not be covered.

#### Questions? Call the Customer Service number on the member's ID card.

Checking eligibility and/or benefit information and/or obtaining prior authorization or pre-notification is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage, including, but not limited to, exclusions and limitations applicable on the date services were rendered. If you have any questions, call the number on the member's ID card.

HEDIS is a registered trademark of the National Committee for Quality Assurance.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSIL. Change Healthcare is an independent third party vendor that is solely responsible for the products or services they offer. BCBSIL makes no endorsement, representations or warranties regarding any products or services provided by third party vendors. If you have any questions about the products or services provided by the vendor, you should contact the vendor directly.

# bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

A newsletter for contracting institutional and professional providers

July 2021

## Blue Choice Opt PPO<sup>SM</sup> Network Expanding to All Illinois Counties

Effective **July 1, 2021**, Blue Cross and Blue Shield of Illinois (BCBSIL) expanded our Blue Choice Opt PPO network (BCO) to cover all Illinois counties. If you're currently contracted with BCBSIL for the Blue Choice PPO<sup>SM</sup> or Blue Choice Preferred PPO<sup>SM</sup> network, as of July 1, 2021, you are an in-network provider for members who have the Blue Options<sup>SM</sup> or the Blue Choice Options<sup>SM</sup> PPO benefit plans.

Organizations who already participate in our Blue Choice PPO or Blue Choice Preferred PPO networks may have received letters welcoming them to BCO, a tiered network that incentivizes members to use participating providers. If you're already a contracted or designated provider in one of the above networks and you received a welcome notice, no action is necessary on your part. The notice was for informational purposes, and your current reimbursement rates will remain in place.

#### bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

A newsletter for contracting institutional and professional providers

July 2021

### Check Eligibility and Benefits: Don't skip this important first step!

Is your patient's membership with Blue Cross and Blue Shield of Illinois (BCBSIL) still active? Are you or your practice/medical group in- or out-of-network for a specific patient? Is prior authorization required for a particular member/service?

#### **Get Answers Up Front**

Benefits will vary based on the service being rendered and individual and group policy elections. It's critical to check eligibility and benefits for each patient before every scheduled appointment. Eligibility and benefit quotes include important information about the patients' benefits, such as membership verification, coverage status and applicable copayment, coinsurance and deductible amounts. Also, the benefit quote may include information on applicable prior authorization or pre-notification requirements.\* When services may not be covered, you should notify members that they may be billed directly.

#### **Don't Take Chances**

Ask to see the member's BCBSIL ID card for current information. Also ask for a driver's license or other photo ID to help guard against medical identity theft. Remind your patients to call the number on their BCBSIL card if they have questions about their benefits.

#### **Use Online Options**

We encourage you to check eligibility and benefits via an electronic 270 transaction through the Availity® Provider Portal or your preferred vendor portal. You may conduct electronic eligibility and benefits inquiries for local BCBSIL members, and out-of-area Blue Plan and Federal Employee Program® (FEP®) members.

#### Learn More

For more information, such as an <u>Availity user guide</u>, refer to the <u>Eligibility and Benefits page</u> on our Provider website. BCBSIL also offers educational webinars with an emphasis on electronic transactions, including eligibility and benefits inquiries. Refer to the <u>Webinars and Workshops page</u> for upcoming dates, times and registration links to sign up now.

\*Note: For commercial non-HMO members, even if prior authorization isn't required, you may still want to submit a

voluntary predetermination request. This step can help avoid post-service medical necessity review. Checking eligibility and benefits can't tell you when to request predetermination, since it's optional. But there's a <u>Medical Policy Reference</u> <u>List</u> on our <u>Predetermination page</u> to help you decide.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSIL. BCBSIL makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity. If you have any questions about the products or services provided by such vendors, you should contact the vendor(s) directly.

Checking eligibility and benefits and/or obtaining prior authorization is not a guarantee of payment of benefits. Payment of benefits is subject to several factors, including, but not limited to, eligibility at the time of service, payment of premiums/contributions, amounts allowable for services, supporting medical documentation, and other terms, conditions, limitations, and exclusions set forth in the member's policy certificate and/or benefits booklet and or summary plan description. Regardless of any prior authorization or benefit determination, the final decision regarding any treatment or service is between the patient and their health care provider.

### bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

conduct a search, view general and payer-specific information and

A newsletter for contracting institutional and professional providers

July 2021

# **Provider Learning Opportunities**

Blue Cross and Blue Shield of Illinois (BCBSIL) offers free workshops and webinars for the independently contracted providers who work with us. These trainings focus on electronic options and other helpful tools and resources. A preview of upcoming training sessions is included below. For more information, refer to our <u>Webinars and Workshops page</u>.

#### **BCBSIL WEBINARS**

save or print results.

To register now for a webinar on the list below, click on your preferred session date.

| Descriptions:  | Dates:  | Session Times:   |
|--|---|------------------|
| Availity® Authorizations Tool We are hosting one-hour webinar sessions for providers to learn how to electronically submit inpatient and outpatient benefit preauthorization requests handled by BCBSIL using Availity's Authorizations tool.  | July 7, 2021<br>July 14, 2021<br>July 21, 2021<br>July 21, 2021 | 11 a.m. to noon  |
| Availity Claim Status We are hosting complimentary webinars for providers to learn how to verify detailed claim status online using Availity's Claim Status tool.  | July 8, 2021<br>July 15, 2021<br>July 22, 2021<br>July 29, 2021 | 11 to 11:30 a.m. |
| Availity Remittance Viewer and Reporting On-Demand These online tools give providers and billing services a convenient way to view claim detail information from the 835 Electronic Remittance Advice (835 ERA) and the Provider Claim Summary (PCS). Attend a webinar to learn how to gain or grant access, | July 22, 2021   | 1 to 2 p.m.      |

| BCBSIL Back to Basics: 'Availity 101'  Join us for a review of electronic transactions, provider tools and helpful online resources.   | July 13, 2021<br>July 20, 2021<br>July 27, 2021 | 11 a.m. to noon               |
|--|---|-------------------------------|
| BCCHP <sup>SM</sup> and MMAI Required Provider Training Webinars If you provide care and services to our Blue Cross Community MMAI (Medicare-Medicaid Plan)SM and/or Blue Cross Community Health Plans <sup>SM</sup> (BCCHP) members, please join us for guided webinars that will review all the provider trainings required by the Centers for Medicare & Medicaid Service (CMS) and/or Illinois Department of Healthcare and Family Services (HFS). | July 21, 2021                                   | 1 to 3 p.m.                   |
| Medicaid HEDIS® 101 Training This training will cover a wide range of quality improvement topics and resources to help improve Healthcare Effectiveness Data and Information Set (HEDIS) rates.  | July 14, 2021<br>July 28, 2021                  | Noon to 1 p.m.                |
| Medicaid HEDIS 102 Training This training is designed for contracted providers working with new BCCHP and MMAI members. We'll review HEDIS measure updates, discuss strategies to sharpen your knowledge of HEDIS measures, and cover the measure year (MY) 2020 and MY 2021 HEDIS technical specifications and general guidelines.  | July 20, 2021                                   | Noon to 1 p.m.                |
| Monthly Provider Hot Topics Webinar  These monthly webinars will be held through December 2021.  They are customized for the BCBSIL contracted provider community. BCBSIL Provider Network Consultants (PNCs) will use this format to share upcoming initiatives, program changes and updates, as well as general network announcements.   | July 14, 2021                                   | 10 to 11 a.m.                 |
| Orientation Webinars for New BCCHP and MMAI Providers These orientation webinars will give you the opportunity to ask the PNCs questions and will highlight topics such as care coordination, third party vendors, claims, prior authorization and required provider training.   | July 13, 2021<br>July 20, 2021                  | 1 to 2 p.m.<br>10 to 11 a.m.  |
| What is Vaccine Confidence?  Join us for a free webinar with Dr. Suzanne R. White, MD, MBA,  FACEP, FACMT, Regional Medical Director employed by Merck &  Co. Learn about possible determinants of and barriers to vaccine  confidence, and provider and team approaches to building vaccine  confidence.  | July 21, 2021<br>July 21, 2021                  | Noon to 1 p.m.<br>3 to 4 p.m. |

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSIL. BCBSIL makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity. If you have any questions about the products or services provided by such vendors, you should contact the vendor(s) directly.

# bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

A newsletter for contracting institutional and professional providers

July 2021

## Reminder: CPT® Codes May Change

As a reminder, Current Procedural Terminology (CPT) codes may change throughout the year due to changes (new, replaced or removed codes) implemented by the American Medical Association (AMA). Refer to the <u>AMA website</u> for more information on CPT codes.

Our online systems are updated to reflect AMA coding changes. Be sure to check eligibility and benefits prior to rendering services to our members to confirm coverage and other important details, such as which services may require prior authorization.

CPT copyright 2020 AMA. All rights reserved. CPT is a registered trademark of the AMA.

Checking eligibility and/or benefits and/or obtaining prior authorization is not a guarantee of payment of benefits. Payment of benefits is subject to several factors, including, but not limited to, eligibility at the time of service, payment of premiums/contributions, amounts allowable for services, supporting medical documentation, and other terms, conditions, limitations, and exclusions set forth in the member's policy certificate and/or benefits booklet and or summary plan description. Regardless of any prior authorization or benefit determination, the final decision regarding any treatment or service is between the patient and their health care provider.

# bcbsil.com/provider

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association